Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents

Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all NHLs and characterized by overexpression of cyclin D1. The last decade has seen the development of many novel treatment approaches in MCL, most notably the class of Bruton's tyrosine kinase inhibitors (BTKi)....

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Neeraj, Mamgain, Mukesh, Chowdhury, Sayan Mullick, Jindal, Udita, Sharma, Isha, Sehgal, Lalit, Epperla, Narendranath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463717/
https://www.ncbi.nlm.nih.gov/pubmed/37626420
http://dx.doi.org/10.1186/s13045-023-01496-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463717/
https://www.ncbi.nlm.nih.gov/pubmed/37626420
http://dx.doi.org/10.1186/s13045-023-01496-4

Ejemplares similares